David Zebrowski
Chief Executive Officer GenKardia
David Zebrowski, PhD, is the Founder and CEO of GenKardia, an early-stage biotechnology company developing novel therapies for heart failure. A seasoned leader in cardiovascular research, he previously served as a tenure-track Assistant Professor at The Chinese University of Hong Kong, where his lab focused on molecular cardiology and cardiac regeneration. Dr. Zebrowski also brings industry experience from his role as a Heart Failure Specialist and member of the Cardiovascular Leadership Team at Novo Nordisk. He currently serves as an Expert Advisor for Nucleate New York, supporting the next generation of biotech innovators.
Seminars
Wednesday 28th January 2026
Conquering Cardiac Fibrosis: A New RNAi Paradigm for Heart Failure
10:00 am
- Leveraging highly specific RNAi therapeutics, directly silencing key pro-fibrotic genes, to halt the underlying disease progression and move beyond symptom management
- Utilizing a novel, targeted delivery platform, enabling efficient extrahepatic delivery to cardiac tissue, to achieve robust efficacy and open new treatment possibilities for patients
- Addressing the root cause of pathological remodeling, by precisely reducing fibrosis and hypertrophy, to restore cardiac function and significantly improve patient quality of life
